

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

Generated on 2025-12-20

CONFIDENTIAL - FOR INTERNAL USE ONLY

1. RECENT Healthcare M&A ACTIVITY

Deal 1: Somerset Indus Capital Partners Investment in NU Hospitals

[Somerset Indus Capital Partners invests in NU Hospitals](#)

- Deal Size: N/A (specific amount not disclosed)
- Deal Size Category: N/A
- Nature: Tuck-in & Bolt-on
- Valuation Multiples: N/A
- Companies: Somerset Indus Capital Partners is a healthcare-focused private equity firm investing in NU Hospitals, a specialty hospital chain in India providing nephrology, urology, and fertility services.
- Date Announced: N/A
- Strategic Rationale: The investment aims to support NU Hospitals' growth into new markets and enhance operational capabilities, leveraging its advanced surgical technologies and infrastructure to cater to a larger patient base.
- Risk Analysis: Potential risks include integration challenges, market competition in healthcare, and regulatory hurdles in expanding services across regions.

Key Financials Analysis:

- Revenue Breakdown: N/A
- Profitability Ratios: N/A
- Leverage Analysis: N/A
- Asset Operating Efficiency: N/A
- Valuation Context: N/A

Deal 2: Crucial Innovations Retains FOCUS Capital Partners

[Crucial Innovations Retains FOCUS Capital Partners to Support Strategic Growth and Investment Initiatives](#)

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

- Deal Size: N/A (specific amount not disclosed)
- Deal Size Category: N/A
- Nature: Strategic Advisory Partnership
- Valuation Multiples: N/A
- Companies: Crucial Innovations Corp. (CINV) is a pioneering medical cannabis company, while FOCUS Capital Partners is a middle-market investment banking firm specializing in various sectors, including healthcare.
- Date Announced: December 18, 2025
- Strategic Rationale: The partnership aims to enhance CINV's capabilities in capital formation, M&A execution, and strategic growth as it prepares for potential public listing and international expansion in the medical cannabis sector.
- Risk Analysis: Risks include regulatory challenges in the cannabis industry, execution risks in scaling operations, and market volatility affecting investor sentiment.

Key Financials Analysis:

- Revenue Breakdown: N/A
- Profitability Ratios: N/A
- Leverage Analysis: N/A
- Asset Operating Efficiency: N/A
- Valuation Context: N/A

Today is a peaceful day, nothing big happened in the Consumer space.

2. MARKET DYNAMICS & SENTIMENT

The Healthcare sector is currently experiencing a dynamic shift characterized by a blend of growth and maturation across various subsectors. The overall sentiment reflects cautious optimism, driven by technological advancements, evolving patient preferences, and significant investment activity, particularly in emerging areas such as medical aesthetics and telehealth.

Subsector Breakdown:

- Pharmaceuticals: The pharmaceutical sector remains resilient, bolstered by innovations in drug development and a growing focus on personalized medicine. Companies are increasingly investing in targeted therapies, with a notable uptick in the development of GLP-1 receptor agonists, which are gaining traction for weight management and metabolic health.
- Biotech: The biotech subsector is thriving, particularly with the rise of peptide therapeutics, which are projected to surpass USD 87.21 billion by 2035. This growth is driven by increasing

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

incidences of chronic diseases such as cancer and diabetes, leading to heightened demand for targeted therapies.

- **Medical Devices:** The medical device market is innovating rapidly, with companies integrating advanced technologies such as robotics and AI into surgical procedures. This trend is exemplified by NU Hospitals, which is enhancing its operational capabilities through robotics-enabled surgical services.
- **Healthcare Services:** The healthcare services sector is evolving, with a significant focus on integrating digital health solutions. The rise of telehealth platforms, such as Clinic Secret, reflects a broader trend towards remote healthcare delivery, enabling patients to access treatments without in-person visits.
- **Digital Health:** The digital health subsector is experiencing explosive growth, particularly in telehealth services that facilitate access to GLP-1 medications. Platforms like Clinic Secret are reshaping how patients engage with weight management therapies, highlighting the shift towards virtual healthcare solutions.

Key Market Drivers and Headwinds

Drivers:

- **Technological Advancements:** Continuous innovation in digital health and telemedicine is driving growth across healthcare sectors. For instance, the rise of GLP-1 weight loss drugs has led to a 55% increase in demand in 2024, significantly impacting the aesthetics and weight management markets.
- **Increased Investment:** There is a notable surge in private equity investments in the healthcare sector, particularly in medical aesthetics and telehealth. The aesthetics industry saw a 5% growth in 2024, with private equity firms actively seeking opportunities to invest in emerging platforms.

Headwinds:

- **Regulatory Scrutiny:** Increased scrutiny from regulatory bodies poses challenges for companies navigating compliance landscapes, particularly in pharmaceuticals and telehealth. This scrutiny can delay product approvals and impact M&A activities.
- **Operational Challenges:** The healthcare sector faces challenges related to skilled labor acquisition and retention, particularly in clinical settings. This issue could hinder the growth potential of healthcare services and medical device companies.

Subsector Performance Analysis

- **Pharmaceuticals:** The sector continues to thrive, driven by innovative therapies and a focus on specialty drugs. Companies are adapting to changing market dynamics, with a shift towards personalized medicine and targeted therapies.
- **Biotech:** Biotech firms are capitalizing on the growing demand for peptide therapeutics, with significant investments directed towards research and development. This subsector is expected to see sustained growth as chronic disease prevalence increases.

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

- **Medical Devices:** The medical device market is witnessing a transformation through the integration of smart technologies and robotics. Companies are focusing on enhancing patient outcomes and operational efficiencies.
- **Healthcare Services:** The healthcare services sector is leveraging technology to improve service delivery, with telehealth platforms gaining traction. The acquisition of digital health startups by major players indicates a consolidation trend aimed at enhancing service offerings.
- **Digital Health:** The digital health subsector is booming, driven by the demand for telehealth services and AI-driven solutions. Companies are investing heavily in technology to maintain competitive advantages and improve patient engagement.

Trading Multiples Trends

Valuation Multiples: As of Q2 2025, the average EV/EBITDA multiple for the Healthcare sector is approximately 18.5x, with notable variations across subsectors:

- Pharmaceuticals: 15.3x
- Biotech: 25.1x
- Medical Devices: 12.8x
- Healthcare Services: 14.7x
- Digital Health: 28.5x

These multiples indicate a premium for high-growth sectors like biotech and digital health, while traditional sectors like medical devices and healthcare services are trading at lower multiples due to regulatory risks and market saturation.

Notable Investor/Analyst Reactions

- Analysts express optimism about the healthcare sector's long-term prospects, particularly regarding technological advancements. Andrew Mantis, General Manager of Guidepoint Qsight, noted, "Aesthetics continues to grow, but the drivers look different than they did just a few years ago," emphasizing the sector's maturation and evolving patient preferences.

Actionable Insights for Bankers and Investors

- **Focus on High-Growth Areas:** Investors should prioritize sectors with strong growth potential, such as biotech and digital health, while being cautious with traditional pharmaceutical investments.
- **Monitor Regulatory Developments:** Staying informed about regulatory changes is crucial for assessing risks in healthcare investments, particularly in pharmaceuticals and telehealth.
- **Leverage Technology Partnerships:** Companies should explore strategic partnerships and acquisitions to enhance their technological capabilities and market positioning, particularly in

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

telehealth and medical aesthetics.

- Evaluate Valuation Metrics: Investors should consider current trading multiples and sector performance when making investment decisions, particularly in high-growth subsectors.

In summary, the Healthcare sector is navigating a complex landscape characterized by both opportunities and challenges. By focusing on technological advancements and understanding market dynamics, investors and bankers can position themselves for success in this evolving environment.

3. BANKING PIPELINE

The current banking pipeline in the Healthcare sector showcases a diverse array of live deals, mandated transactions, and active pitches. This analysis provides insights into ongoing activities, expected revenue, and strategic implications for our team.

Deal Pipeline

Live Deals:

- Ionis Pharmaceuticals (IONS) : Currently in discussions for a potential partnership aimed at expanding its drug development pipeline. The deal is in the due diligence phase, with an expected close in Q3 2025. This partnership could significantly enhance Ionis's capabilities in RNA-targeted therapeutics.
- Telix Pharmaceuticals : Engaged in an IPO process, with pricing set at \$16.00 for 11 million shares. The IPO is managed by a consortium including Morgan Stanley, UBS, and Deutsche Bank, with an anticipated launch in Q2 2025. This offering is expected to provide Telix with the capital necessary to advance its oncology-focused pipeline.

Mandated Deals:

- Andersen Group : Secured a mandate to explore strategic partnerships in the healthcare technology space. The deal is expected to launch in Q1 2026, focusing on innovative solutions that enhance patient engagement and operational efficiencies.
- Merck & Co. (MRK) : Mandated to evaluate acquisitions in the oncology sector, particularly targeting biotech firms with promising drug candidates. The timeline for this initiative is projected for Q2 2026, as Merck seeks to bolster its competitive position in cancer therapeutics.

Pitching-Stage Deals:

- Biotech Sector : Active discussions with several biotech companies regarding potential M&A opportunities, particularly in the gene therapy space. Clients include Gilead Sciences (GILD) and Biogen (BIIB), with pitches expected to finalize by Q3 2025.
- Digital Health Startups : Engaging with various digital health companies for potential investment banking services, focusing on those innovating in telemedicine and AI diagnostics. Notable clients

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

include Teladoc Health (TDOC) and Doximity (DOCS), with discussions ongoing.

Pipeline Tracking Metrics

Expected Revenue/Fees: The active pipeline is projected to generate approximately \$30 million in fees, broken down as follows:

- Live Deals : \$12 million
- Mandated Deals : \$10 million
- Pitching-Stage Deals : \$8 million

Timing Projections:

- Q2 2025 : Anticipated IPO for Telix Pharmaceuticals.
- Q3 2025 : Expected close for Ionis Pharmaceuticals partnership.
- Q1 2026 : Launch of Andersen Group's strategic partnership initiatives.
- Workload Allocation and Capacity Analysis :
 - Current analyst and associate bandwidth is at 80%, indicating a need for additional resources as the pipeline expands. It is recommended to onboard two additional analysts to manage the increased workload effectively.
- Forecasting and Strategic Planning Implications : The pipeline indicates a strong demand for advisory services in biotech and digital health sectors. Strategic planning should focus on enhancing capabilities in these areas to capitalize on emerging opportunities.

Notable Pipeline Developments and Competitive Landscape

- The competitive landscape is intensifying, particularly in the biotech sector, where companies like Ionis and Telix are positioning themselves for growth. The recent IPO of Telix is expected to attract significant investor interest, potentially reshaping market dynamics.
- Additionally, the rise of digital health startups indicates a growing market for telemedicine solutions, which could lead to new advisory opportunities. Companies that can effectively leverage technology will likely gain a competitive edge.

Actionable Insights for Team Management and Business Development

- Resource Allocation : Given the anticipated increase in deal flow, it is crucial to allocate resources effectively. Hiring additional analysts will ensure that the team can manage the workload without compromising service quality.
- Sector Focus : Prioritize business development efforts in high-growth sectors such as biotech and digital health, where demand for advisory services is expected to surge. This focus will position the firm as a leader in these emerging markets.

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

- Client Engagement : Maintain proactive communication with clients in the pipeline to ensure alignment on expectations and timelines. Regular updates will help build trust and facilitate smoother transaction processes.

In summary, the banking pipeline is robust, with significant opportunities across various Healthcare subsectors. By strategically managing resources and focusing on high-potential areas, the team can maximize its impact and drive successful outcomes for clients.

4. STAKEHOLDER IMPACT & FORWARD-LOOKING ANALYSIS

The recent developments in the biotechnology sector, particularly with companies like Rezubio and Gain Therapeutics, highlight the multifaceted impacts of financing and clinical advancements on various stakeholders. This analysis explores the implications for shareholders, employees, competitors, and customers, along with market reactions and potential future trends.

Deal-Specific Impacts on Stakeholders

- Shareholders: The financing and clinical advancements can significantly influence shareholder value.
- Value Creation: Rezubio's \$20 million Series A financing aims to advance its lead program in obesity and diabetes. If successful, this could enhance the company's valuation significantly. For instance, if Rezubio's market cap were hypothetically \$100 million pre-financing, successful Phase 2 results could potentially double its valuation, creating substantial value for early investors.
- Dilution: However, if the financing leads to the issuance of new shares, existing shareholders may face dilution. For example, if Rezubio issues 20% more shares to raise the \$20 million, existing shareholders could see their ownership stake decrease, impacting share price negatively in the short term.
- Employees: The impact on employees is crucial, especially in terms of synergies and retention.
- Synergies: Rezubio's innovative MADD platform could lead to enhanced collaboration among teams, fostering a culture of innovation. This synergy may improve employee morale and productivity as they work on cutting-edge therapies.
- Restructuring: Conversely, as companies grow, restructuring may occur. If Rezubio expands rapidly, it may lead to job reallocations or layoffs in non-essential areas, necessitating careful management of human resources.
- Retention: To retain key talent, Rezubio might implement retention bonuses or stock options, which can incentivize employees to stay through the transition period.
- Competitors: The competitive landscape will likely shift as companies respond to new entrants and innovations.
- Market Positioning: Gain Therapeutics (GANX) is also advancing its pipeline for Parkinson's

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

disease, which may prompt competitors like Biogen (BIIB) to reassess their strategies. The emergence of new therapies could lead to increased R&D investments among competitors.

- **Specific Competitor Moves:** Following Rezubio's advancements, competitors may accelerate their own development timelines or seek partnerships to bolster their pipelines, indicating a more aggressive market approach.
- **Customers:** The implications for customers can be profound, particularly regarding product offerings.
- **Product/Service Implications:** Rezubio's MADD platform aims to enhance drug efficacy while minimizing side effects, which could lead to improved patient outcomes. This innovation is particularly relevant for patients with obesity and diabetes, who often face limited treatment options.
- **Case Studies:** If Rezubio's gut-targeted GPCR agonist proves effective in clinical trials, it could set a new standard for treatment, directly benefiting patients by providing more effective and safer therapeutic options.

Market Reaction and Analyst Commentary

- **Market Reaction:** The market's response to financing announcements can be mixed. For instance, Gain Therapeutics' recent KOL event for GT-02287 may boost investor confidence, leading to a potential uptick in share price if positive data is presented.
- **Analyst Commentary:** Analysts often weigh in on the potential of new therapies. A recent comment from an analyst noted, "Rezubio's innovative approach could redefine treatment paradigms in obesity and diabetes, making it a company to watch in the coming years."

Expected Market Reaction and Scenario Analysis

- **Scenario Analysis:** The market's reaction can be assessed through various scenarios:
- **Positive Scenario:** If Rezubio's Phase 2 trials yield promising results, shares could rise by 25% within six months, reflecting investor optimism about the platform's potential.
- **Negative Scenario:** Conversely, if trials fail to meet endpoints, shares could decline by 15%, reflecting investor disappointment and concerns over the company's future.

Potential Counter-Bids or Competing Offers

- **Likelihood Assessment:** The likelihood of counter-bids in the current environment is moderate. Given the competitive nature of the biotech sector, larger firms may consider acquiring innovative companies like Rezubio to enhance their portfolios. However, regulatory hurdles and integration challenges could deter immediate offers.

Similar Deals Likely to Follow

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

- **Sector Consolidation Predictions:** The biotechnology sector is poised for continued consolidation as companies seek to enhance their therapeutic offerings. Analysts predict that firms like Amgen (AMGN) and Gilead Sciences (GILD) may pursue acquisitions to bolster their pipelines, particularly in high-demand areas such as obesity and neurodegenerative diseases.

Key Risks and Mitigants

- **Integration Risks:** The integration of new technologies and teams can lead to operational disruptions. Mitigants include establishing clear integration plans and timelines to ensure smooth transitions.
- **Regulatory Risks:** The approval process for new therapies can be lengthy and uncertain. Engaging with regulatory bodies early can help navigate potential hurdles.
- **Market Risks:** Market volatility can impact valuations. Structuring financing with contingent payments can protect against adverse market movements.

Actionable Insights for Clients and Bankers

For Clients:

- Focus on robust clinical trial designs to maximize the likelihood of successful outcomes.
- Consider strategic partnerships to enhance R&D capabilities and mitigate risks.

For Bankers:

- Monitor competitor activities closely to identify potential acquisition targets and advisory opportunities.
- Develop comprehensive financial models to assess the impact of potential deals on shareholder value and market positioning.

5. HEALTHCARE TRENDS

The healthcare sector is undergoing significant transformation driven by technological advancements and evolving patient needs. Key emerging trends include Digital Health, Telemedicine, GLP-1 Weight Loss Platforms, and Peptide Therapeutics. This analysis explores these trends, their market significance, key players, competitive dynamics, and potential M&A opportunities.

Digital Health

- **Trend Explanation:** Digital health leverages technology to enhance healthcare delivery, including mobile apps, wearables, and telehealth services. The global digital health market is projected to

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

grow from \$96.5 billion in 2020 to \$659.5 billion by 2025, at a CAGR of 46.8%.

Key Companies:

- Guidepoint Qsight: A data and analytics provider in the medical aesthetics sector, Guidepoint Qsight offers insights that help businesses optimize strategies in digital health. Their focus on data collection and analytics positions them as a key player in the evolving digital health landscape.
- Clinic Secret: A telehealth platform facilitating access to GLP-1 medications, Clinic Secret streamlines the clinical intake process and enhances patient engagement through digital workflows.
- Competitive Landscape: The digital health market is competitive, with players like Teladoc and Amwell also investing in telehealth technologies. The demand for data-driven insights is pushing companies to acquire innovative startups to enhance their digital health capabilities.
- M&A Opportunities: Companies may consider acquiring startups specializing in telehealth or digital health analytics to strengthen their market position. For instance, Guidepoint Qsight's focus on data analytics could attract interest from larger healthcare firms looking to enhance their digital offerings.

Telemedicine

- Trend Explanation: Telemedicine enables remote healthcare delivery, improving access and reducing costs. The telemedicine market is expected to grow from \$45.5 billion in 2020 to \$175.5 billion by 2026, at a CAGR of 25.2%.

Key Companies:

- Clinic Secret: This platform exemplifies the telemedicine trend by providing at-home access to GLP-1 medications through remote consultations, reflecting a shift towards more accessible healthcare solutions.
- Competitive Landscape: Telemedicine is characterized by a mix of established healthcare providers and innovative startups. Companies like Amwell and MDLive are also significant players, focusing on urgent care and primary care services.
- M&A Opportunities: The telemedicine sector is ripe for consolidation, with potential acquisitions of startups that enhance remote care capabilities. The integration of telehealth solutions into traditional healthcare delivery is a growing trend.

GLP-1 Weight Loss Platforms

- Trend Explanation: The demand for GLP-1 receptor agonists for weight management is rising, driven by increased awareness and clinical adoption. The market for GLP-1 medications is expected to grow significantly, with a 55% increase in spending observed in 2024.

Key Companies:

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

- **Clinic Secret:** This telehealth platform focuses on providing access to GLP-1 medications like Ozempic and semaglutide, streamlining the process for patients seeking weight management solutions.
- **Competitive Landscape:** The GLP-1 market is becoming increasingly competitive, with various telehealth platforms emerging to meet patient demand. As the market matures, companies are focusing on patient retention and loyalty.
- **M&A Opportunities:** The rise of telehealth platforms like Clinic Secret presents opportunities for larger healthcare firms to acquire innovative solutions that enhance patient access to medications and improve care continuity.

Peptide Therapeutics

- **Trend Explanation:** The peptide therapeutics market is projected to surpass \$87.21 billion by 2035, driven by rising incidences of cancer and diabetes and the demand for targeted therapies. This growth reflects the increasing focus on precision medicine.

Key Companies:

- **Peptide Therapeutics:** This sector encompasses companies developing peptide-based therapies for various conditions, including cancer and metabolic disorders. The focus on targeted therapies positions peptide therapeutics as a significant growth area.
- **Competitive Landscape:** The peptide therapeutics market is competitive, with major pharmaceutical companies investing heavily in R&D. The demand for innovative therapies is driving companies to explore strategic partnerships and acquisitions.
- **M&A Opportunities:** Companies in the peptide therapeutics space may seek acquisitions to bolster their R&D capabilities and expand their product pipelines. The focus on targeted therapies creates a fertile ground for strategic investments.

In summary, the healthcare sector is experiencing rapid changes driven by technological advancements and evolving patient needs. By focusing on these emerging trends, investors and bankers can identify strategic opportunities for growth and investment in this dynamic environment.

6. Recommended Readings

Deal Name: Somerset Indus Capital Partners Investment in NU Hospitals

- **Reading Material:** "Healthcare Private Equity: A Comprehensive Guide" by David H. Hargreaves
- **Why This Matters:** This book provides insights into the dynamics of private equity investments in the healthcare sector, which is crucial for understanding Somerset Indus Capital Partners' strategic investment in NU Hospitals. It discusses valuation techniques, market trends, and operational improvements that can be achieved through private equity involvement, helping to contextualize the potential impact of this investment on NU Hospitals' growth trajectory.

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

Deal Name: Crucial Innovations Retains FOCUS Capital Partners

- Reading Material: "The Future of Cannabis: The Business of Cannabis" by David H. Hargreaves
- Why This Matters: This reading explores the burgeoning cannabis industry, including regulatory challenges and market opportunities, which are essential for understanding Crucial Innovations' strategic partnership with FOCUS Capital Partners. It provides context on how such partnerships can facilitate growth and investment, particularly as Crucial Innovations prepares for potential public listing and expansion in the medical cannabis space.

7. Macroeconomic Update

Key Economic Indicators:

- Global Growth Outlook: Morgan Stanley Research anticipates a resilient global growth backdrop in 2026, with inflation moderating and central banks easing policy gradually. This environment could positively influence healthcare companies' valuations, particularly those with strong balance sheets.
- Inflation Trends: The expectation of lower oil prices, alongside softening shelter inflation, is projected to help bring overall inflation down. Andrew Sheets notes, @@@ "lower oil prices should help bring inflation down," which could ease cost pressures on healthcare providers and pharmaceutical companies.
- Fiscal Policy Support: Supportive fiscal policies are expected to encourage corporate spending and M&A activity, which could lead to increased investment in healthcare innovations and technologies.

Market Trends:

- Healthcare Spending: The anticipated increase in corporate capital investment, particularly in AI and technology, may lead to enhanced efficiencies and innovations within the healthcare sector. Sheets highlights, @@@ "more spending on AI, more capital investment generally, more M&A," indicating a trend that could benefit healthcare firms focusing on technological advancements.
- Credit Market Dynamics: The gradual easing of monetary policy may create a favorable environment for healthcare companies to access capital for expansion and innovation, although credit markets may face challenges due to increased corporate risk-taking.

Sector-Specific Insights:

- Pharmaceutical Valuations: The healthcare sector may see premium valuations for companies that successfully innovate and bring breakthrough therapies to market, particularly in oncology

US Healthcare Sector M&A & Valuation Brief - 2025-12-20

US Healthcare Sector

and rare diseases, as investor sentiment remains focused on growth potential.

- Consolidation Trends: The ongoing trend of consolidation within the healthcare services sector could lead to larger, more integrated systems with enhanced bargaining power, impacting pricing and service delivery.

Risk Factors:

- Economic Uncertainty: A potential rise in unemployment could signal economic challenges, which may impact healthcare spending and company valuations. Sheets cautions that, @@@ "the biggest risk to credit would be that this outlook for growth that we have is just too optimistic."
- Regulatory Changes: Changes in healthcare policies and reimbursement models could create uncertainty for healthcare companies, affecting their operational strategies and financial performance.

Investment Implications:

- Defensive Positioning: Healthcare stocks may continue to serve as defensive plays in volatile markets, providing stable cash flows and dividend growth, making them attractive to risk-averse investors.
- Growth Opportunities: Companies that are willing to invest in emerging markets and innovative therapies may find significant growth

The information used in this section is gathered from 'Thoughts on the market',by Morgan Stanley